NOTE

🌱 created from: Relapsed Refractory Disease of Diffuse large B-cell lymphoma

glofitamab

Obinutuzumab + Glofitamab, Complete response: 39% (95% CI, 32 to 48); 63% cytokine release syndrome, 62% grade 3 or higher adverse events.

follow STARGLO

Glofitamab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Information

• Design: Phase 2 study
• Number of patients: 155
• Patients characteristics: Patients with relapsed or refractory diffuse large B-cell lymphoma who had received at least two lines of therapy previously
• Agent: Glofitamab, a bispecific antibody that recruits T cells to tumor cells
• Treatment line: Third-line therapy or later
• Trial Name or NCT Number: Not provided (ClinicalTrials.gov number not specified)

Results

• Primary endpoint: Complete response rate
• Complete response rate: 39% (95% CI, 32 to 48)
• Median time to complete response: 42 days (95% CI, 42 to 44)
• Duration of response: 78% of complete responses were ongoing at 12 months
• Progression-free survival: 37% (95% CI, 28 to 46) at 12 months

Other findings

• Adverse events: 63% of patients experienced cytokine release syndrome, and 62% experienced adverse events of grade 3 or higher
• Discontinuation due to adverse events: 9% of patients

Summary The study demonstrates that glofitamab therapy is effective in patients with relapsed or refractory diffuse large B-cell lymphoma, with a complete response rate of 39%. However, more than half of the patients experienced adverse events of grade 3 or higher, including cytokine release syndrome.